EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

“Undruggable KRAS”: druggable after all

Adrienne D Cox, Channing J Der

Genes & Development · 05.12.2024

DOI: 10.1101/gad.352081.124 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes & Development, online erschienen am 05.12.2024. Verfasst von Adrienne D Cox und 1 weiteren Autor:innen. Beteiligte Einrichtung: Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA; cjder@med.unc.edu adrien…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 31-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, Pancreatic Cancer Action Network.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The three RAS genes ( HRAS , KRAS , and NRAS ) comprise the most frequently mutated oncogene family in cancer. KRAS is the predominant isoform mutated in cancer and is most prevalently mutated in major causes of cancer deaths including lung, colorectal, and pancreatic cancers. Despite extensive academic and industry efforts to target KRAS, it would take nearly four decades before approval of the first clinically effective KRAS inhibitors for the treatment of KRAS mutant lung cancer. We revisit past anti-KRAS strategies and painful lessons learned and then focus on the rapidly evolving landscape of direct RAS inhibitors, resistance mechanisms, and potential combination treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)HumansMutationNeoplasmsAnimalsAntineoplastic AgentsDrug Resistance, NeoplasmMolecular Targeted Therapy

Stichwörter der Autor:innen

CRCKRASNSCLCPDACcolorectal cancernon-small cell lung cancerpancreatic ductal adenocarcinoma

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA; cjder@med.unc.edu adrienne_cox@med.unc.edu.
  • Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
  • Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • Pancreatic Cancer Action Network
  • Department of Defense
  • The Blue Ribbon Run
  • Julie M. Brown and Christina Gianoplus Foundation for Colon Cancer Research

Zitieren

APA

Cox, A. D., & Der, C. J. (2024). “Undruggable KRAS”: druggable after all. Genes & Development. https://doi.org/10.1101/gad.352081.124

Vancouver

Cox AD, Der CJ. “Undruggable KRAS”: druggable after all. Genes & Development. 2024. doi:10.1101/gad.352081.124

BibTeX
@article{Cox2024,
  author = {Cox, Adrienne D and Der, Channing J},
  title = {“Undruggable KRAS”: druggable after all},
  journal = {Genes & Development},
  year = {2024},
  doi = {10.1101/gad.352081.124}
}
Kostenlos starten →